Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease

Neuroscience

Volumn 94, Issue 3, 1999, Pages 685-696

  Sihver, W ^a   Gillberg, P G ^b,c   Svensson, A L ^d   Nordberg, A ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Human temporal cortex; Nicotinic receptor binding; Quantitative autoradiography; Vesicular acetylcholine transport sites

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR; CYSTEINE; EPIBATIDINE; NICOTINE; TRITIUM; ALKALOID; AZOCINE DERIVATIVE; CARRIER PROTEIN; CYTISINE; FUSED HETEROCYCLIC RINGS; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLIZINE DERIVATIVE; SLC18A3 PROTEIN, HUMAN; VESAMICOL; VESICULAR ACETYLCHOLINE TRANSPORTER; VESICULAR TRANSPORT PROTEIN;

ACETYLCHOLINE BRAIN LEVEL; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING SITE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MEMBRANE VESICLE; PRIORITY JOURNAL; TEMPORAL CORTEX; TISSUE DISTRIBUTION; TRANSPORT KINETICS; AGE; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE; TEMPORAL LOBE;

ACETYLCHOLINE; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALOIDS; ALZHEIMER DISEASE; AUTORADIOGRAPHY; AZOCINES; BICYCLO COMPOUNDS, HETEROCYCLIC; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NICOTINE; PIPERIDINES; PYRIDINES; QUINOLIZINES; REFERENCE VALUES; TEMPORAL LOBE; TRITIUM; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 0032590008     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00295-X     Document Type: Article

References (97)

1. Alafuzoff I., Iqbal K., Fridén H., Adolfsson R., Winblad B. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariant data analysis. Acta neuropath. 74:1987;209-225.
2. 3H]vesamicol binding in brain: autoradiographic distribution, pharmacology, and effects of cholinergic lesions. Synapse. 2:1988;486-493.
3. Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta neuropath. 61:1983;101-108.
4. Arendt T., Schindler C., Bruckner M.K., Eschrich K., Bigl V., Zedlick D., Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 17:1997;516-529.
5. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebr. Cortex. 1:1991;103-116.
6. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:1992;631-639.
7. Aubert I., Poirier J., Gauthier S., Ouirion R. Multiple cholinergic markers are unexpectedly not altered in the rat dentate gyrus following entorhinal cortex lesions. J. Neurosci. 14:1994;2476-2484.
8. Aubert I., Cecyre D., Gauthier S., Quirion R. Comparative ontogenic profile of cholinergic markers, including nicotinic and muscarinic receptors, in the rat brain. J. comp. Neurol. 369:1996;31-55.
9. Bertolino M., Kellar K.J., Vicini S., Gillis R.A. Nicotinic receptor mediates spontaneous GABA release in the rat dorsal motor nucleus of the vagus. Neuroscience. 79:1997;671-681.
10. Bogdanovic N. and Morris J. H. (1995) Diagnostic criteria for Alzheimer's disease in multi-centre brain banking. In Neuropathological Diagnostic Criteria for Brain Banking (eds Cruz-Sanchez et al.), pp. 20-29. IOS, Amsterdam.
11. Brodmann K. (1909) Vergleichende Lokalisationslehre der Grosshirnrinde in ihren Prinzipien dargestellt auf Grund des Zellenbaues. Barth, Leipzig.
12. Chu C.C., Tranel D., Damasio A.R., Van Hoesen G.W. The autonomic-related cortex: pathology in Alzheimer's disease. Cerebr. Cortex. 7:1997;86-95.
13. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
14. Court J.A., Piggott M.A., Perry E.K., Barlow R.B., Perry R.H. Age-associated decline in high affinity nicotine binding in human brain frontal cortex does not correlate with the changes in choline acetyltransferase activity. Neurosci. Res. Commun. 10:1992;125-133.
15. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
16. Custers F.G., Leysen J.E., Stoof J.C., Herscheid J.D. Vesamicol and some of its derivatives: questionable ligands for selectively labeling acetylcholine transporters in rat brain. Eur. J. Pharmac. 338:1997;177-183.
17. Efange S.M.N., Mach R.H., Smith C.R., Khare A.B., Foulon C., Akella S.K., Childers S.R., Parsons S.M. Vesamicol analogues as sigma ligands. Biochem. Pharmac. 49:1995;791-797.
18. Efange S.M.N., Garland E.M., Staley J.K., Khare A.B., Mash D.C. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol. Aging. 18:1997;407-413.
19. Etienne P., Robitaille Y., Wood P., Gauthier S., Nair N.P.V., Quirion R. Nucleus basalis neuronal loss. Neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience. 19:1986;1279-1291.
20. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1986;1948-1954.
21. Fonnum F. A rapid radiochemical method of the determination of choline acetyltransferase. J. Neurochem. 24:1975;407-409.
22. Gattaz W.F., Maras A., Cairns N.J., Levy R., Forstl H. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiat. 37:1995;13-17.
23. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Molec. Pharmac. 48:1995;774-782.
24. Geula C., Mesulam M.M. Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience. 33:1989;469-481.
25. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cerebr. Cortex. 6:1996;165-177.
26. Geula C., Mesulam M.M., Saroff D.M., Wu C.K. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J. Neuropath. exp. Neurol. 57:1998;63-75.
27. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:1997;17-24.
28. Gotti C., Fornasari D., Clementi F. Human neuronal nicotinic receptors. Prog. Neurobiol. 53:1997;199-237.
29. Haigh J.R., Noremberg K., Parsons S.M. Acetylcholine active transport by rat brain synaptic vesicles. NeuroReport. 5:1994;773-776.
30. 3H]cytisine. Neuroscience. 62:1994;929-944.
31. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Molec. Brain Res. 66:1999;94-103.
32. Henke H., Lang W. Cholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-type patients. Brain Res. 267:1983;281-291.
33. Hicks B.W., Rogers G.A., Parsons S.M. Purification and characterization of a non-vesicular vesamicol-binding-protein from electric organ and demonstration of a protein in mammalian brain. J. Neurochem. 57:1991;509-519.
34. Hof P.R., Bouras C. Object recognition deficit in Alzheimer' disease: possible disconnection of the occipito-temporal component of the visual system. Neurosci. Lett. 122:1991;53-63.
35. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Molec. Pharmac. 48:1995;280-287.
36. Hyman B.T., Gomez-Isla T. Alzheimer's disease is a laminar, regional, and neural system specific disease, not a global brain disease. Neurobiol. Aging. 15:1994;353-354.
37. Kandel E. (1991) Perception of motion, depth, and form. In Principles of Neuronal Science (eds Kandel E. R. et al.), pp. 440-466. Prentice Hall International, London.
38. 3H]Vesamicol binding in human brain cholinergic deficiency disorders. Neurosci. Lett. 177:1990;347-352.
39. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., Wieland D.M., Koeppe R.A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. 40:1996;399-410.
40. Kupfermann I. (1991) Learning and memory. In Principles of Neuronal Science (eds Kandel E. R. et al.), pp. 997-1009. Prentice Hall International, London.
41. London E.D., Ball M.J., Waller S.B. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem. Res. 14:1989;745-750.
42. Marshall I.G., Parsons S.M. The vesicular acetylcholine transport system. Trends Neurosci. 10:1987;174-177.
43. 3H]epibatidine. Brain Res. 801:1998;143-149.
44. Marutle A., Warpman U., Bogdanovic N., Lannfelt L. and Nordberg A. (1999) Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish APP 670/671 mutation. J. Neurochem. 72, 1161-1169.
45. 3H]epibatidine. Med. chem. Res. 4:1994;528-537.
46. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
47. Mesulam M.M. Human brain cholinergic pathways. Prog. Brain Res. 84:1990;231-241.
48. Mesulam M.M., Geula C. Overlap between acetycholinesterase-rich and choline acetytransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res. 577:1992;112-120.
49. Miyai I., Ueno S., Yorifuji S., Fujimura H., Tarui S. Alterations in neocortical expression of nicotinic acetylcholine receptor mRNAs following unilateral lesions of the rat nucleus basalis magnocellularis. J. neural Transm. 82:1990;79-91.
50. Morris C.M., Massey H.M., Benjamin R., Leake A., Broadbent C., Griffiths M., Lamb H., Brown A., Ince P.G., Tyrer S., Thompson P., McKeith I.G., Edwardson J.A., Perry R.H., Perry E.K. Molecular biology of Apo E alleles in Alzheimer's and non-Alzheimer's dementias. J. neural Transm. 47:(Suppl.):1996;205-218.
51. Newhouse P.A., Sunderland T., Tariot P.N., Blumhardt C.L., Weingartner H., Mellow A., Murphy D.L. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology. 95:1988;171-175.
52. 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J. neural Transm. 67:1986;275-285.
53. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-119.
54. Nordberg A., Adem A., Nilsson L., Romanelli L., Zhang X. Heterogeneous cholinergic nicotinic receptors in the CNS. NATO ASI Series. H25:1988;331-349.
55. Nordberg A., Adem A., Hardy J., Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci. Lett. 86:1988;317-321.
56. Nordberg A., Nilsson-Håkansson L., Adem A., Hardy J., Alafuzoff I., Lai Z., Herrera-Marschitz M., Winblad B. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog. Brain Res. 79:1989;353-362.
57. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. neural Transm. 2:1990;215-224.
58. Nordberg A., Alafozoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J. Neurosci. Res. 31:1992;103-111.
59. 11C]nicotine in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. assoc. Disord. 9:1995;21-27.
60. Pascual J., Fontan A., Zarranz J.J., Berciano J., Florez J., Pazos A. High-affinity choline uptake carrier in Alzheimer's disease: implications for the cholinergic hypothesis of dementia. Brain Res. 552:1991;170-174.
61. 3H]Epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J. Pharmac. exp. Ther. 275:1995;1030-1034.
62. Perry E.K., Smith C.J., Court J.A., Perry R.H. Cholinergic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. neural Transm. 2:1990;149-158.
63. 3H]nicotine binding in human cortex: relative abundance in subicular complex. J. chem. Neuroanat. 5:1992;399-405.
64. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotinic binding sites in Parkinson's disease, Lewy body disease and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
65. Perry E.K., Court J.A., Lloyd S., Johnson M., Griffiths M.H., Spurden D., Piggott M.A., Turner J., Perry R.H. β-Amyloidosis in normal aging and transmitter signaling in human temporal lobe. Ann. N.Y. Acad. Sci. 777:1996;388-392.
66. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., Gilfix B.M., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. natn. Acad. Sci. USA. 92:1995;12,260-12,264.
67. 3H]hemicholinium-3. J. neural Transm. 8:1994;161-169.
68. Rogers J., Morrison J.H. Quantitative morphology and regional and laminar distribution of senile plaques in Alzheimer's disease. J. Neurosci. 5:1985;2801-2808.
69. Roghani A., Shirzadi A., Butcher L.L., Edwards R.H. Distribution of the vesicular transporter for acetylcholine in the rat central nervous system. Neuroscience. 82:1998;1195-1212.
70. Rossner S., Schliebs R., Perez-Polo J.R., Wiley R.G., Bigl V. Differential changes in cholinergic markers from selected brain regions after specific immunolesion of the rat cholinergic basal forebrain system. J. Neurosci. Res. 40:1995;31-43.
71. Rubboli F., Court J.A., Sala C., Morris C., Chini B., Perry E., Clementi F. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur. J. Neurosci. 6:1994;1596-1604.
72. 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, and rats with basal forebrain lesions. Neuroscience. 35:1990;327-333.
73. Sahakian B., Jones G., Levy R., Gray J., Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br. J. Psychiat. 154:1989;797-800.
74. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. A. Rev. Neurosci. 16:1993;403-443.
75. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D., Roses A.D. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
76. Schröder H., Zilles K., Maelicke A., Hajos F. Immunohisto- and cytochemical localization of cortical nicotinic cholinoceptors in rat and man. Brain Res. 502:1989;287-295.
77. Schröder H., Giacobini E., Struble R.G., Zilles K., Maelicke A. Nicotinic cholinoceptive neurones of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging. 12:1991;259-262.
78. Shimohama S., Kamiya S., Taniguchi T., Akagawa K., Kimura J. Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem. biophys. Res. Commun. 236:1997;239-242.
79. 3H]epibatidine in vitro autoradiography. Neuroscience. 85:1998;1121-1133.
80. Sparks D.L., Beach T.G., Lukas R.J. Immunohistochemical localization of nicotinic beta2 and alpha4 receptor subunits in normal human brain and individuals with Lewy body and Alzheimer's disease: preliminary observations. Neurosci. Lett. 256:1998;151-154.
81. Svensson A.L., Warpman U., Hellstrom-Lindahl E., Bogdanovic N., Lannfelt L., Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci. Lett. 232:1997;37-40.
82. Tariot P.N. Alzheimer's disease: an overview. Alzheimer Dis. assoc. Disord. 8:1994;S4-S11.
83. Terry R.D., DeTeresa R., Hansen L.A. Neocortical cell counts in normal human adult aging. Ann. Neurol. 21:1987;530-539.
84. Terzano S., Court J.A., Fornasari D., Griffiths M., Spurden D.P., Lloyd S., Perry R.H., Perry E.K., Clementi F. Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. Molec. Brain Res. 63:1998;72-78.
85. Thorne B., Potter P.E. Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function. Brain Res. Bull. 38:1995;121-127.
86. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Age-related changes in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human frontal cortex and hippocampus. Neurosci. Lett. 245:1998;139-142.
87. Van Hoesen G.W., Solodkin A. Some modular features of temporal cortex in humans as revealed by pathologic changes in Alzheimer's disease. Cerebr. Cortex. 3:1993;465-475.
88. Vidal C. Nicotinic potentiation of glutamatergic synapses in the prefrontal cortex: new insight into the analysis of the role of nicotinic receptors in cognitive function. Drug Dev. Res. 31:1994;120-126.
89. Wannan G., Prior C., Marshall I.G. α-Adrenoceptor blocking properties of vesamicol. Eur. J. Pharmac. 102:1991;29-34.
90. Warburton D.M. Nicotine as a cognitive enhancer. Prog. Neuropsychopharmac. biol. Psychiat. 16:1992;181-191.
91. Warpman U., Nordberg A. Epibatidine and ABT-418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains. NeuroReport. 6:1995;2419-2423.
92. Warpman U., Friberg L., Gillespie A., Hellström-Lindahl E., Zhang X., Nordberg A. Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells. J. Neurochem. 70:1998;2028-2037.
93. Wenk G.L., Mobley S.L. Choline acetyltransferase activity and vesamicol binding in Rett syndrome and in rats with nucleus basalis lesions. Neuroscience. 73:1996;79-84.
94. 3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology. 38:1988;720-723.
95. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98.
96. Yang X., Criswell H.E., Breese G.R. Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on γ-aminobutyric acid-containing neurons. J. Pharmac. exp. Ther. 276:1996;482-489.
97. Zawia N., Arendash G.W., Wecker L. Basal forebrain cholinergic neurons in aged rat brain are more susceptible to ibotenate-induced degeneration than neurons in young adult brain. Brain Res. 589:1992;333-337.